×




Amyris Biotechnologies: Commercializing Biofuel Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Amyris Biotechnologies: Commercializing Biofuel case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Amyris Biotechnologies: Commercializing Biofuel case study is a Harvard Business School (HBR) case study written by Gary P. Pisano, Alison Berkley Wagonfeld. The Amyris Biotechnologies: Commercializing Biofuel (referred as “Amyris Biotechnologies” from here on) case study provides evaluation & decision scenario in field of Technology & Operations. It also touches upon business topics such as - Value proposition, Growth strategy, Marketing, Operations management, Product development, Project management, Risk management, Sustainability, Technology.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Amyris Biotechnologies: Commercializing Biofuel Case Study


In 2009, Amyris Biotechnologies was building a plant in Brazil that used synthetic biology to convert sugarcane into both renewable fuels and renewable chemicals. The Amyris' marketing team was investigating the commercial interest for both types of products, while the research and development team and the operations group were building processes that could accommodate both as well. CEO John Melo hoped to have commercial product available in 2011; however, he realized that pursuing both chemicals and fuels added even more complexity to a business that was already executing multiple development steps in parallel. The case looks at the various strategic and operational decisions facing Melo as he planned the company's optimal commercialization strategy.


Case Authors : Gary P. Pisano, Alison Berkley Wagonfeld

Topic : Technology & Operations

Related Areas : Growth strategy, Marketing, Operations management, Product development, Project management, Risk management, Sustainability, Technology




Calculating Net Present Value (NPV) at 6% for Amyris Biotechnologies: Commercializing Biofuel Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10014496) -10014496 - -
Year 1 3454949 -6559547 3454949 0.9434 3259386
Year 2 3981965 -2577582 7436914 0.89 3543935
Year 3 3947691 1370109 11384605 0.8396 3314557
Year 4 3249658 4619767 14634263 0.7921 2574034
TOTAL 14634263 12691912




The Net Present Value at 6% discount rate is 2677416

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Profitability Index
2. Net Present Value
3. Payback Period
4. Internal Rate of Return

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Amyris Biotechnologies shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Amyris Biotechnologies have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.






Formula and Steps to Calculate Net Present Value (NPV) of Amyris Biotechnologies: Commercializing Biofuel

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Technology & Operations Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Amyris Biotechnologies often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Amyris Biotechnologies needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10014496) -10014496 - -
Year 1 3454949 -6559547 3454949 0.8696 3004303
Year 2 3981965 -2577582 7436914 0.7561 3010938
Year 3 3947691 1370109 11384605 0.6575 2595671
Year 4 3249658 4619767 14634263 0.5718 1858003
TOTAL 10468915


The Net NPV after 4 years is 454419

(10468915 - 10014496 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10014496) -10014496 - -
Year 1 3454949 -6559547 3454949 0.8333 2879124
Year 2 3981965 -2577582 7436914 0.6944 2765253
Year 3 3947691 1370109 11384605 0.5787 2284543
Year 4 3249658 4619767 14634263 0.4823 1567158
TOTAL 9496079


The Net NPV after 4 years is -518417

At 20% discount rate the NPV is negative (9496079 - 10014496 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Amyris Biotechnologies to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Amyris Biotechnologies has a NPV value higher than Zero then finance managers at Amyris Biotechnologies can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Amyris Biotechnologies, then the stock price of the Amyris Biotechnologies should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Amyris Biotechnologies should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What can impact the cash flow of the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What will be a multi year spillover effect of various taxation regulations.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

Understanding of risks involved in the project.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Amyris Biotechnologies: Commercializing Biofuel

References & Further Readings

Gary P. Pisano, Alison Berkley Wagonfeld (2018), "Amyris Biotechnologies: Commercializing Biofuel Harvard Business Review Case Study. Published by HBR Publications.


AAP Implantate AG SWOT Analysis / TOWS Matrix

Healthcare , Medical Equipment & Supplies


Galaxy Surfactants SWOT Analysis / TOWS Matrix

Basic Materials , Chemical Manufacturing


ENN Energy SWOT Analysis / TOWS Matrix

Utilities , Natural Gas Utilities


Vivimed Labs Ltd SWOT Analysis / TOWS Matrix

Basic Materials , Chemical Manufacturing


Sasbadi SWOT Analysis / TOWS Matrix

Services , Printing & Publishing


Milbon Co Ltd SWOT Analysis / TOWS Matrix

Consumer/Non-Cyclical , Personal & Household Prods.